Ovo Labs

Ovo Labs is a preclinical-stage biotech developing 'egg rejuvenation' therapeutics to address the primary reason for IVF failure: chromosomal errors in aging eggs. Founded by world-leading reproductive scientists and clinicians, the company aims to boost IVF success rates by 20-30% for women under 35 and by 3-5 times for women aged 35-45. With a strong academic foundation and a leadership team combining deep scientific expertise with business strategy, Ovo Labs is positioned to tackle a significant unmet need in the large and growing global fertility market.

Platform based on pioneering research into oocyte biology and chromosomal segregation errors. Aims to develop pharmacologic 'egg rejuvenation' therapeutics that improve egg quality by targeting the molecular mechanisms of age-related decline, thereby enhancing IVF success rates.

The competitive landscape includes IVF clinics optimizing procedures, companies offering adjunct diagnostic tools (like PGT-A), and a few early-stage biotechs exploring concepts like mitochondrial enhancement or other pharmacological approaches to improve oocyte quality. Ovo Labs differentiates through its deep, publication-backed foundational science from world-leading experts specifically focused on chromosomal segregation errors.